<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3494">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515147</url>
  </required_header>
  <id_info>
    <org_study_id>CV-NCOV-002</org_study_id>
    <nct_id>NCT04515147</nct_id>
  </id_info>
  <brief_title>A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19</brief_title>
  <official_title>COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults &gt;60 Years of Age and 18 to 60 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CureVac AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CureVac AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose&#xD;
      administrations of investigational SARS-CoV-2 mRNA vaccine (CVnCoV) at different dose levels&#xD;
      and to evaluate the humoral immune response after 1 and 2 dose administrations of CVnCoV.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">November 9, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 9, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Solicited Local Adverse Events</measure>
    <time_frame>7 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale</measure>
    <time_frame>7 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Solicited Local Adverse Events</measure>
    <time_frame>7 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Solicited Systemic Adverse Events</measure>
    <time_frame>7 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale</measure>
    <time_frame>7 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Solicited Systemic Adverse Events</measure>
    <time_frame>7 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine</measure>
    <time_frame>7 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Unsolicited Adverse Events</measure>
    <time_frame>28 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of Unsolicited Adverse Events per the FDA Toxicity Grading Scale</measure>
    <time_frame>28 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine</measure>
    <time_frame>28 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline to Day 393</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine</measure>
    <time_frame>Baseline to Day 393</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with One or More Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Baseline to Day 393</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with One or More Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine</measure>
    <time_frame>Baseline to Day 393</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies</measure>
    <time_frame>Day 29</time_frame>
    <description>Measured using Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies</measure>
    <time_frame>Day 43</time_frame>
    <description>Measured using Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum</measure>
    <time_frame>Day 29</time_frame>
    <description>Measured using Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum</measure>
    <time_frame>Day 43</time_frame>
    <description>Measured using Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies</measure>
    <time_frame>Day 29</time_frame>
    <description>Measured using Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies</measure>
    <time_frame>Day 43</time_frame>
    <description>Measured using Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies</measure>
    <time_frame>Day 29</time_frame>
    <description>Measured using an activity assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies</measure>
    <time_frame>Day 43</time_frame>
    <description>Measured using an activity assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum</measure>
    <time_frame>Day 29</time_frame>
    <description>Measured using an activity assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum</measure>
    <time_frame>Day 43</time_frame>
    <description>Measured using an activity assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies</measure>
    <time_frame>Day 29</time_frame>
    <description>Measured using an activity assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies</measure>
    <time_frame>Day 43</time_frame>
    <description>Measured using an activity assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Solicited Local Adverse Events Following the Booster Vaccine</measure>
    <time_frame>7 days after booster vaccination</time_frame>
    <description>During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale Following the Booster Vaccine</measure>
    <time_frame>7 days after booster vaccination</time_frame>
    <description>During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited Local Adverse Events Following the Booster Vaccine</measure>
    <time_frame>7 days after booster vaccination</time_frame>
    <description>During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Solicited Systemic Adverse Events Following the Booster Vaccine</measure>
    <time_frame>7 days after booster vaccination</time_frame>
    <description>During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale Following the Booster Vaccine</measure>
    <time_frame>7 days after booster vaccination</time_frame>
    <description>During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited Systemic Adverse Events Following the Booster Vaccine</measure>
    <time_frame>7 days after booster vaccination</time_frame>
    <description>During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine Following the Booster Vaccine</measure>
    <time_frame>7 days after booster vaccination</time_frame>
    <description>During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Unsolicited Adverse Events Following the Booster Vaccine</measure>
    <time_frame>28 days after booster vaccination</time_frame>
    <description>During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Unsolicited Adverse Events per the FDA Toxicity Grading Scale Following the Booster Vaccine</measure>
    <time_frame>28 days after booster vaccination</time_frame>
    <description>During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine Following the Booster Vaccine</measure>
    <time_frame>28 days after booster vaccination</time_frame>
    <description>During Part 1, booster vaccinations will be administered to participants in Group 3 and a sub-group of participants in Group 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies</measure>
    <time_frame>Day 57, Day 85, Day 180, Day 208 and Day 393</time_frame>
    <description>Measured using Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum</measure>
    <time_frame>Day 57, Day 85, Day 180, Day 208 and Day 393</time_frame>
    <description>Measured using Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies</measure>
    <time_frame>Day 57, Day 85, Day 180, Day 208 and Day 393</time_frame>
    <description>Measured using Enzyme-Linked Immunosorbent Assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies</measure>
    <time_frame>Day 57, Day 85, Day 180, Day 208 and Day 393</time_frame>
    <description>Measured using an activity assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum</measure>
    <time_frame>Day 57, Day 85, Day 180, Day 208 and Day 393</time_frame>
    <description>Measured using an activity assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies</measure>
    <time_frame>Day 57, Day 85, Day 180, Day 208 and Day 393</time_frame>
    <description>Measured using an activity assay.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">674</enrollment>
  <condition>Coronavirus</condition>
  <condition>Covid19</condition>
  <condition>SARS-CoV-2</condition>
  <condition>Severe Acute Respiratory Syndrome</condition>
  <arm_group>
    <arm_group_label>Part 1, Group 1: CVnCoV 6 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Group 2: CVnCoV 6 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Group 3: CVnCoV 12 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be between the ages of 18 to 60 years old.&#xD;
CVnCoV will be administered again as a booster vaccination on Day 180 in a sub-group of participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Group 4: CVnCoV 12 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.&#xD;
CVnCoV will be administered again as a booster vaccination on Day 57 or Day 180 in a sub-group of participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Group 5: Hepatitis A vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Group 6: Pneumococcal vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Group 1: CVnCoV 12 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Group 2: Hepatitis A vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Group 3: CVnCoV 12 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged over 60 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Group 4: Pneumococcal vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CVnCoV 6 μg</intervention_name>
    <description>Participants will receive an intramuscular injection by needle in the deltoid area.</description>
    <arm_group_label>Part 1, Group 1: CVnCoV 6 μg</arm_group_label>
    <arm_group_label>Part 1, Group 2: CVnCoV 6 μg</arm_group_label>
    <other_name>CV07050101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CVnCoV 12 μg</intervention_name>
    <description>Participants will receive an intramuscular injection by needle in the deltoid area.</description>
    <arm_group_label>Part 1, Group 3: CVnCoV 12 μg</arm_group_label>
    <arm_group_label>Part 1, Group 4: CVnCoV 12 μg</arm_group_label>
    <other_name>CV07050101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis A vaccine</intervention_name>
    <description>Participants will receive an intramuscular injection by needle in the deltoid area.</description>
    <arm_group_label>Part 1, Group 5: Hepatitis A vaccine</arm_group_label>
    <arm_group_label>Part 2, Group 2: Hepatitis A vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal vaccine</intervention_name>
    <description>Participants will receive an intramuscular injection by needle in the deltoid area.</description>
    <arm_group_label>Part 1, Group 6: Pneumococcal vaccine</arm_group_label>
    <arm_group_label>Part 2, Group 4: Pneumococcal vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CVnCoV 12μg</intervention_name>
    <description>Participants will receive an intramuscular injection by needle in the deltoid area.</description>
    <arm_group_label>Part 2, Group 1: CVnCoV 12 µg</arm_group_label>
    <arm_group_label>Part 2, Group 3: CVnCoV 12 µg</arm_group_label>
    <other_name>CV07050101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female participants ≥18 years of age. A healthy participant is&#xD;
             defined as an individual who is in good general health, according to the&#xD;
             Investigator's assessment. Chronic health conditions are acceptable if the condition&#xD;
             is considered well controlled with treatment according to the discretion of the&#xD;
             Investigator.&#xD;
&#xD;
          -  Expected to be compliant with protocol procedures and available for clinical follow-up&#xD;
             through the last planned visit.&#xD;
&#xD;
          -  Physical examination without clinically significant findings according to the&#xD;
             Investigator's assessment.&#xD;
&#xD;
          -  Body mass index (BMI) ≥18.0 and ≤32.0 kg/m^2.&#xD;
&#xD;
          -  Female participants of childbearing potential: at the time of enrollment, negative&#xD;
             human chorionic gonadotropin (hCG) pregnancy test (serum) for women presumed to be of&#xD;
             childbearing potential on the day of enrollment. On Day 1 (pre-vaccination): negative&#xD;
             urine pregnancy test (required if serum pregnancy test was performed more than 3 days&#xD;
             before).&#xD;
&#xD;
          -  Female participants of childbearing potential must use highly effective methods of&#xD;
             birth control from 2 weeks before the first administration of the trial vaccine until&#xD;
             3 months following the last administration. The following methods of birth control are&#xD;
             considered highly effective when used consistently and correctly:&#xD;
&#xD;
               -  Combined (estrogen and progestogen containing) hormonal contraception associated&#xD;
                  with inhibition of ovulation (oral, intravaginal or transdermal);&#xD;
&#xD;
               -  Progestogen-only hormonal contraception associated with inhibition of ovulation&#xD;
                  (oral, injectable or implantable);&#xD;
&#xD;
               -  Intrauterine devices;&#xD;
&#xD;
               -  Intrauterine hormone-releasing systems;&#xD;
&#xD;
               -  Bilateral tubal occlusion;&#xD;
&#xD;
               -  Vasectomized partner;&#xD;
&#xD;
               -  Sexual abstinence (periodic abstinence [e.g., calendar, ovulation, symptothermal&#xD;
                  and post-ovulation methods] and withdrawal are not acceptable).&#xD;
&#xD;
          -  Male participants should be instructed not to get their partners pregnant during the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any investigational or non-registered product (vaccine or drug) other than the&#xD;
             trial vaccine within 28 days preceding the administration of the trial vaccine, or&#xD;
             planned use during the trial period.&#xD;
&#xD;
          -  Receipt of any other vaccines within 28 days prior to enrollment in this trial or&#xD;
             planned receipt of any vaccine within 28 days of trial vaccine administration (primary&#xD;
             dose or booster dose).&#xD;
&#xD;
          -  Receipt of any investigational SARS-CoV-2 or other coronavirus vaccine prior to the&#xD;
             administration of the trial vaccine.&#xD;
&#xD;
          -  Any treatment with immunosuppressants or other immune-modifying drugs (including, but&#xD;
             not limited to, corticosteroids, biologicals, and methotrexate) within 6 months prior&#xD;
             to the administration of the trial vaccine or planned use during the trial, with the&#xD;
             exception of topically-applied, inhaled, or intranasal steroids.&#xD;
&#xD;
          -  Use of hormonal therapy for gender reassignment.&#xD;
&#xD;
          -  Any medically diagnosed or suspected immunosuppressive or immunodeficient condition&#xD;
             based on medical history and physical examination, including known human&#xD;
             immunodeficiency virus infection, hepatitis B virus infection, and hepatitis C virus&#xD;
             infection.&#xD;
&#xD;
          -  History of immune-mediated or autoimmune disease.&#xD;
&#xD;
          -  History of angioedema (known C1 inhibitor deficiency).&#xD;
&#xD;
          -  History of anaphylaxis or allergy to any component of CVnCoV or aminoglycoside&#xD;
             antibiotics.&#xD;
&#xD;
          -  History of or current alcohol and/or drug abuse.&#xD;
&#xD;
          -  Participants who are active smokers, were active smokers within the last year&#xD;
             (including any vaping in the last year), or have a total smoking history ≥10 pack&#xD;
             years. A pack year is calculated by multiplying the number of packs of cigarettes&#xD;
             smoked per day by the number of years the person has smoked.&#xD;
&#xD;
          -  History of virologically-confirmed SARS, MERS, or COVID-19 disease or known exposure&#xD;
             (without any personal protective equipment) to an individual with confirmed COVID-19&#xD;
             disease or SARS-CoV-2 infection within the past 2 weeks.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the 3 months&#xD;
             preceding the administration of any dose of the trial vaccine.&#xD;
&#xD;
          -  Presence or evidence of significant uncontrolled acute or chronic medical or&#xD;
             psychiatric illness. Significant medical or psychiatric illnesses include but are not&#xD;
             limited to:&#xD;
&#xD;
               -  Uncontrolled respiratory disease (e.g., chronic obstructive pulmonary disease,&#xD;
                  asthma), including use of the following asthma medications: intravenous&#xD;
                  corticosteroids, leukotriene modifiers, biologics.&#xD;
&#xD;
               -  Uncontrolled cardiovascular disease (e.g., congestive heart failure,&#xD;
                  cardiomyopathy, ischemic heart disease, history of stroke, peripheral artery&#xD;
                  disease, pulmonary embolism).&#xD;
&#xD;
               -  History of myocarditis or pericarditis as an adult.&#xD;
&#xD;
               -  Diabetes mellitus (insulin-dependent).&#xD;
&#xD;
               -  Uncontrolled neurological disorders or Guillain-Barré syndrome or history of&#xD;
                  seizure, except for febrile seizures during childhood.&#xD;
&#xD;
               -  Current or past malignancy, unless completely resolved without sequelae for &gt;5&#xD;
                  years.&#xD;
&#xD;
          -  Foreseeable non-compliance with protocol, as judged by the Investigator.&#xD;
&#xD;
          -  For female participants: pregnancy or lactation.&#xD;
&#xD;
          -  Participants with impaired coagulation or any bleeding disorder in whom an&#xD;
             intramuscular injection or a blood draw is contraindicated. This includes participants&#xD;
             on treatment with anticoagulants (e.g., vitamin K antagonists, novel oral&#xD;
             anticoagulants, and heparin). Use of platelet aggregation inhibitors is not&#xD;
             exclusionary.&#xD;
&#xD;
          -  Participants employed by the Sponsor, Investigator, or trial site, or relatives of&#xD;
             research staff working on this trial.&#xD;
&#xD;
          -  Participants considered at the Investigator's discretion to be at increased risk of&#xD;
             exposure to COVID-19 disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centro de vacunación internacional - CEVAXIN Panama Clinic</name>
      <address>
        <city>Panama city</city>
        <zip>0831</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigación Nutricional</name>
      <address>
        <city>Lima</city>
        <zip>Lima - 12</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
    <country>Peru</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>SARS</keyword>
  <keyword>COVID</keyword>
  <keyword>Safety</keyword>
  <keyword>Reactogenicity</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

